GUANGZHOU, China, Sept. 15, 2026 (GLOBE NEWSWIRE) — GAC AION today officially launched the 2027 AION i60, a mass-market five-seat SUV available in both battery electric vehicle (BEV) and range-extended electric vehicle (REEV) variants. The vehicle is powered by WeRide WRD 3.0, WeRide’s one-stage end-to-end Advanced Driver Assistance System (ADAS) solution, which has achieved eight championships at the China Urban Intelligent Driving Competition. WRD 3.0 is now deployed in the 2027 AION i60, marking its transition to mass production.

The system delivers a broad range of L2++ intelligent driving features, including enabling Navigate on Autopilot (NDA) activation directly from a parked state, navigation-free assisted driving in park and campus environments, remote parking assistance, three-point turn assistance, and Parking-space-to-Parking-space (P2P) navigation assistance in ground-level parking facilities.

Following the AION N60, the newly launched 2027 AION i60 marks another major milestone in the partnership between WeRide and GAC. The collaboration is now expanding from single-model validation to scaled deployment across multiple vehicle platforms, paving the way for broader cooperation in the future.

2027 AION i60 is equipped with WeRide WRD 3.0, WeRide's One-Stage End-to-End ADAS Solution

2027 AION i60 is equipped with WeRide WRD 3.0, WeRide’s One-Stage End-to-End ADAS Solution

Featured on the 2027 AION i60, WRD 3.0 is WeRide’s latest-generation one-stage end-to-end ADAS solution, and the culmination of nearly a decade of L4 autonomous driving development and operational experience, bringing proven capabilities to the L2++ ADAS segment.

WeRide has deployed autonomous driving services in over 60 cities across 13 countries worldwide over the past decade. Through real-world operations across diverse road environments, climates, and traffic conditions globally, the company’s Level 4 fully driverless autonomous vehicles have accumulated extensive experience in understanding and responding to complex traffic scenarios, road user behaviors, and rare edge-case situations.

Leveraging WeRide One, WeRide’s proprietary universal autonomous driving technology platform, alongside WeRide WITT, its Physical AI Cognitive Foundation Model, and WeRide GENESIS, its proprietary general-purpose simulation model, WRD 3.0 translates extensively validated Level 4 autonomous driving capabilities into holistic scene understanding and continuous decision-making capabilities for L2++ mass-produced passenger vehicles.

As a result, the 2027 AION i60 can accurately understand the intentions of different road users, anticipate changes in traffic dynamics, and deliver smooth driving assistance that closely aligns with human driving intuition. The system demonstrates driving performance approaching that of an experienced human driver across a wide range of scenarios, while exhibiting strong capabilities in handling challenging edge cases.

From the AION N60 to the AION i60, WeRide and GAC Group are advancing advanced driver assistance technologies from small-scale validation to large-scale mass production. WeRide will continue working closely with GAC AION and other GAC Group brands to expand the deployment of WRD 3.0 across additional vehicle models, helping bring advanced intelligent driving technologies to the mainstream consumer market.

About WeRide
WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 60 cities across 13 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune’s 2025 Change the World and 2025 Future 50 lists.

Media Contact
pr@weride.ai

Safe Harbor Statement
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a289af5f-ea3a-4cf1-ad56-9c4acd657c0d

SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisors Bill Wagner, CFP®, RICP®, Scott Sennett and Andrew Kocukov of Horizon Wealth Management Group have joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platforms. The team reported serving approximately $385 million in advisory, brokerage and retirement plan assets* and joins LPL from Wells Fargo Advisors Financial Network.

Based in Wichita, Kan., Horizon Wealth Management Group serves clients through a comprehensive, planning-based approach focused on helping individuals and families navigate retirement with confidence. The ensemble practice combines the expertise of three partners and Operations Manager Julie Starns to deliver personalized guidance that extends beyond traditional investment management. The team’s clients are primarily retirees and individuals approaching retirement, with a majority of the practice focused on helping clients manage the distribution phase of their financial lives.

At the core of the firm’s philosophy is a commitment to understanding “the why behind the what” before making recommendations. Through detailed financial planning, retirement income strategies, estate planning guidance, long-term care discussions and ongoing support, the team works to help clients address both the financial and personal aspects of retirement.

“We believe successful retirement planning is about much more than managing money,” Wagner said. “It’s about helping people create a fulfilling life after they leave the workforce and ensuring they have a strategy in place to support the future they envision. Every recommendation starts with understanding what’s important to our clients and the goals they want to accomplish. That level of planning helps us build deeper relationships and provide guidance that extends well beyond investment management.”

The firm’s team-based approach enables Horizon Wealth Management Group to provide specialized expertise across multiple areas of financial planning. Together, the team collaborates on estate planning and client strategy discussions, allowing them to deliver comprehensive service while remaining highly accessible to clients.

Why Horizon Wealth Management Group Chose LPL

The team selected LPL for its advanced technology, robust financial planning capabilities and dedicated service model. As Horizon Wealth Management Group evaluated potential partners, the advisors sought a platform that would enable them to operate more efficiently, enhance client service and support their planning-focused business model.

“We spent significant time researching potential partners and ultimately felt LPL was best positioned to support both our team and our clients,” Wagner said. “The technology is exceptional, and the financial planning tools align closely with our approach. The dedicated service model will help us deliver an even better client experience. Having direct access to a consistent service team means faster answers, greater efficiency and more time spent where it matters most: helping families pursue their goals.”

Marc Cohen, Chief Growth Officer at LPL Financial, said, “What stands out about Horizon Wealth Management Group is the team’s belief that meaningful advice begins with understanding each client’s goals, priorities, and vision for the future. Bill, Scott, and Andrew bring distinct expertise to that work, operating as one team so clients benefit from the collective experience and dedication of the entire firm. We’re honored to welcome Horizon Wealth Management Group to LPL and look forward to supporting the team as they expand their impact while preserving the valued relationships that have shaped their success.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Horizon Wealth Management Group and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking # 1173772

Proprietary technology currently used across EzFill’s 141-truck fleet in 15 markets combines dynamic routing and scheduling, driver and route analytics, live fuel monitoring and end-to-end fuel reconciliation

MIAMI, FL, Sept. 15, 2026 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed and delivered, today announced that its mobile fueling subsidiary, EzFill, is developing a white-label version of its proprietary telematics platform to license to third-party fleet operators, fuel distributors and mobile fueling companies.

Developed to manage EzFill’s own mobile fueling operations, the platform is currently deployed across the Company’s fleet of 141 trucks operating in 15 markets. The technology brings together routing, scheduling, driver and route performance, real-time truck fuel levels and fuel delivery data in a single operating system, giving managers detailed visibility into fleet activity and fuel movement.

“We built this technology to solve problems we face every day in our own operation,” said Yehuda Levy, CEO of EzFill. “It gives our managers visibility into how our trucks are being routed, how drivers are performing, how much fuel is on each truck and how much fuel is being delivered at every stop. We believe other fleet and fuel operators face many of the same challenges, and we are now preparing to license the platform, including a white-label version that can be adapted for their operations.”

“The strongest validation we’ve received comes from our largest customer, one of the world’s largest online retailers, which views our platform and its integration with their back-end systems as a differentiator, and has encouraged us to make it available to its other fueling providers. When a customer of that scale tells you your software is the reason they work with you, it says something about the technology,” said Michael D. Farkas, Founder and CEO of NextNRG. “EzFill developed this platform to optimize its own operations, and it has become integral to how we manage the fleet. We believe the same technology can help other fleet and fuel operators improve visibility, efficiency and accountability across their operations.”

Unlike conventional fleet tracking systems that primarily monitor vehicle location, EzFill’s platform connects routing, operational and fuel data to provide a more complete view of each route and delivery. The system evaluates planned routes against those actually driven, identifies deviations and additional stops, and uses live fuel volumes on each truck to help managers plan routes based on available fuel, scheduled stops and delivery requirements.

At the fuel-delivery level, the platform adds another layer of accountability by tracking fuel throughout the delivery process. It monitors fuel levels within EzFill’s trucks, fuel delivered at each stop and vehicle-level fuel data captured through EzFill’s Bluetooth-enabled fuel monitoring technology, allowing the system to reconcile fuel moving into and out of each truck and compare delivered volumes against the receiving vehicle’s fuel level.

Licensing the platform represents an opportunity for EzFill to extend technology developed for its own operations to a broader market. Initial interest from fleet and fuel operators has been strong, and the Company is in active discussions with prospective licensees. Potential applications include mobile fueling companies, fuel distributors, and other fleet-intensive businesses looking to improve routing, scheduling, fuel accountability, and driver performance.

The Company expects to provide additional information as development progresses.

About EzFill

EzFill is a leading on-demand mobile fueling service and a subsidiary of NextNRG, Inc. (NASDAQ: NXXT). EzFill delivers on-demand mobile fueling to commercial customers, including vehicle fleets, businesses and events, eliminating the need for drivers to leave their routes or job sites to refuel.

About NextNRG, Inc.

NextNRG, Inc. (NextNRG) is Powering What’s Next by deploying its AI-driven Smart Controller, a proprietary AI technology that continuously optimizes how energy is generated, stored, and consumed. The Company deploys the controller within microgrids at commercial, healthcare, municipal, industrial and federal sites, and at a utility scale through the Next Utility Operating System®.

NextNRG also sells EV chargers, is advancing wireless in-motion charging, and operates one of the nation’s largest on-demand mobile fueling fleets through EzFill.

To learn more, visit www.nextnrg.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expect,” “intends,” “will,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time.

NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by NextNRG. Although NextNRG’s forward-looking statements reflect the good faith judgment of NextNRG, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update these forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

Investor Relations Contact
NextNRG, Inc.
Sharon Cohen
SCohen@nextnrg.com

Media Contact
HCM for NextNRG
nextnrg@hannahcranstonmedia.com

Patent No. US 12,633,155 B1 covers deep-learning methods that automatically count vehicle occupants at highway speed, addressing a long-standing enforcement gap for transportation agencies

SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) — OMNIQ CORP. (OTCQB: OMQS) (“OMNIQ” or the “Company”), a leading provider of AI-based computer vision solutions, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 12,633,155 B1, titled “HOV detection system using multiband line-scan imagery.” The application was originally filed in 2020 and names OMNIQ’s Yoram Hofman as inventor.

The patent covers methods and systems for automatically determining the number of occupants inside a moving vehicle. As a vehicle crosses a detection line, roadside cameras capture line-scan images in two separate infrared bands. Because human skin reflects infrared light differently than vehicle interiors, seats, and clothing, comparing the two bands increases contrast on occupants’ faces. Deep-learning networks then locate the vehicle’s windows, identify faces within them, and validate the count across front and side views. The system pairs the occupancy count with license plate recognition (LPR) and, consistent with privacy requirements, blurs occupants’ faces in the evidentiary images it produces.

Economic Context

A representative deployment of the Company’s patented HOV enforcement technology could generate approximately $1.6 million in annual revenue. Based on the Company’s assessment of comparable deployment opportunities nationwide, the total annual U.S. addressable market is estimated at approximately $218 million. The estimate is based on approximately 136 addressable HOV and high occupancy toll facilities nationwide, after excluding jurisdictions where automated vehicle occupancy enforcement is legally restricted. The Federal Highway Administration identified 145 HOV and high occupancy toll facilities across the United States, providing an established infrastructure base for potential deployment.

“Our machine vision platform is already counting, identifying, and classifying vehicles in the field every day. This patent protects the next layer, seeing accurately inside the vehicle, at speed, day or night,” said Shai Lustgarten, CEO of OMNIQ. “Agencies have been asking for a reliable way to enforce occupancy requirements without putting officers on the shoulder of a freeway. We believe the methods protected by this patent are a credible answer, and we intend to continue investing in the intellectual property that differentiates our technology.”

The problem it addresses

HOV, carpool, and express lanes are among the primary tools transportation agencies use to manage congestion without building new road capacity. Their effectiveness depends on compliance, and compliance is difficult to enforce. Manual enforcement requires an officer to visually count occupants in vehicles traveling at highway speed, then execute a traffic stop, frequently on a shoulder with limited safe pull-off space.

The consequences are measurable. As cited in the patent’s background, the California Highway Patrol has indicated violation rates reaching as much as 39% of vehicles in a diamond lane during peak commute hours, with local transportation experts estimating an average of 19% to 24%. Every violating vehicle represents both degraded travel-time performance for compliant carpoolers and, on tolled express lanes, uncollected revenue.

Occupancy verification is also a requirement adjacent to markets that OMNIQ already serves, including tolling, border crossings, airport curbside and rideshare management, and controlled-access facilities, all of which rely on the same underlying vehicle-recognition stack.

How OMNIQ uses the technology today

The occupancy-detection methods build directly on the machine vision platform OMNIQ has deployed commercially. OMNIQ’s vehicle recognition technology, which identifies license plate, make, color, and state, is in service across thousands of sites in the United States and three sites globally, in applications including toll roads and border crossings, airport rideshare and curbside operations, law enforcement, gateless parking, and critical infrastructure access control.

The patented occupancy detection technology is already deployed at two active U.S. and one international site. These deployments provide real-world validation of the technology under live traffic conditions.

ABOUT OMNIQ
OMNIQ CORP. (or omniQ) uses patented and proprietary artificial intelligence (AI) technology to deliver machine vision image processing solutions, including data collection, real-time surveillance, and monitoring for supply chain management, homeland security, public safety, traffic & parking management, and access control applications.

The technology and services we provide help our clients move people, assets, and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments.

Our principal solutions include hardware, software, communications, automated management services, technical services, and support. Our highly tenured team of professionals has the knowledge and expertise to simplify the integration process for our customers. We deliver practical problem-solving solutions backed by numerous customer references.

Privacy and Data Security Commitment

OMNIQ solutions are built to meet the privacy and data protection requirements of the agencies that use them. Data is processed and stored in a private network, and access is limited to authorized personnel at the contracting agency. Data is retained and purged according to the agency’s policy and applicable state law. OMNIQ does not sell plate data or share it with third parties for commercial purposes.

For more information about OMNIQ Corp. and its innovative solutions, please visit www.omniq.com.

INFORMATION ABOUT FORWARD LOOKING STATEMENTS

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate,” “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward-looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at SEC.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless otherwise required by law.

Contact

Company

IR@OMNIQ.COM

HAYDEN IR:
Brett Maas
(646) 536-7331
brett@haydenir.com

James Carbonara
(646)-755-7412
james@haydenir.com

LAS VEGAS, NV, Sept. 15, 2026 (GLOBE NEWSWIRE) — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced, together with its joint venture partner and global biotechnology company Austrianova, the successful completion of comprehensive adventitious agent and viral testing of its GMP Master Cell Bank (MCB), from which its Working Cell Bank (WCB) was recently established. With the testing completed and the WCB now successfully established, Avaí Bio and Austrianova have completed an important milestone in the development of the Company’s genetically modified α-Klotho-producing cell line. 

The testing confirmed that the MCB, and in turn, the WCB are free of a broad range of potentially contaminating viruses and other adventitious agents. The testing included more than 30 viruses, including significant human and animal pathogens such as human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), human cytomegalovirus (HCMV), and hepatitis B and C viruses. Additional testing confirmed the absence of other potential contaminants, including bacteria, mycoplasma, fungi, and yeast. 

The testing was conducted by an experienced, accredited third-party laboratory in accordance with applicable industry guidelines, including those established by the U.S. Food and Drug Administration (FDA). 

The completion of this testing represents an important step in the development and characterization of the Company’s α-Klotho-producing cell line. The cells, which were in-licensed from Klothea Bio, have been genetically modified to overexpress α-Klotho, a protein associated with healthy aging and protection against age-related disease. 

Klothonova, the joint venture company formed by Avaí Bio and Austrianova, is now focused on further characterization of the Klotho-producing cells and on using the WCB to establish optimal production parameters for the development of the Cell-in-a-Box® encapsulated cell product. 

“We are pleased to announce the successful completion of this important testing milestone,” said Chris Winter, Chief Executive Officer of Avaí Bio. “The results provide additional confirmation of the safety and quality of our Master and Working Cell Banks and allow us, together with our partner, to advance the next stages of development. We remain focused on progressing toward our goal of developing long-term, safe and effective cell-based therapies for healthy aging and longevity.” 

Dr. Brian Salmons, Chief Executive Officer of Austrianova, added, “Comprehensive testing of cell banks for viruses and other adventitious agents is an essential component of biomanufacturing and an important prerequisite for advancing cell-based products toward clinical development. We are pleased that the independently conducted testing confirmed that the MCB, and by default, the WCB were negative for all viruses included in the testing panel. With this milestone completed, we are advancing toward the next steps in the development and production of the Cell-in-a-Box® encapsulated clinical product.” 

This latest milestone follows the joint venture agreement signed in September 2025, which established Klothonova as a Nevada-based company equally owned by Avaí Bio and Austrianova’s affiliate, SG Austria Pte. Ltd. The joint venture was established to develop a sustainable approach to the production and delivery of α-Klotho—often referred to as the “longevity protein,” a key regulatory protein that is well documented for its anti-aging and protective effects on organs—in patients using Cell-in-a-Box® encapsulated cell-based therapies. 

About Avaí Bio, Inc. 

Avaí Bio, Inc. is an emerging biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies. 

About Austrianova (SGAustria Pte. Ltd.) 

Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies. 

More information about Avaí Bio can be found at https://www.avaibio.com  

More information about Austrianova can be found at https://austrianova.com 

You can also follow us on social media at: 

https://x.com/AvaiBio 

https://www.facebook.com/AvaiBio 

https://www.facebook.com/Austrianova 


Forward-Looking Statements 

Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

CONTACT: Avaí Bio, Inc. 

info@avaibio.com 

ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa’s engineered synthetic iMSC platform beyond oncology

Positive ERNA-201 findings add to a growing body of preclinical evidence supporting the versatility of Ernexa’s synthetic iMSC platform and its ability to deliver engineered therapeutic factors in disease

Company is concentrating near-term resources on ERNA-101 while broadening its oncology strategy and advancing next-generation iMSC candidates across additional high-need cancer indications

ERNA-201 remains an important platform asset with demonstrated preclinical proof-of-concept, preserving future development and strategic optionality

CAMBRIDGE, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced positive preliminary preclinical results for ERNA-201, its synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapy engineered to express anti-inflammatory factors, while outlining a sharpened oncology strategy designed to accelerate the Company’s transition into the clinic and expand the long-term potential of its proprietary synthetic iMSC platform.

In preliminary studies using the collagen-induced arthritis (CIA) model, an industry-standard preclinical model for rheumatoid arthritis and inflammatory joint disease, several ERNA-201 lead candidates demonstrated reductions in disease severity relative to untreated controls, including improvements in clinical arthritis scores consistent with the therapy’s intended anti-inflammatory mechanism of action.

Ernexa believes these results represent an important scientific milestone: ERNA-201 demonstrated meaningful preclinical proof-of-concept in inflammatory disease, providing additional evidence that the Company’s engineered iMSC platform can be programmed to deliver therapeutically relevant factors across distinct disease settings.

With this platform validation in hand, Ernexa is concentrating its near-term capital and operational resources on what management believes represents the Company’s most immediate opportunity to create value for patients and shareholders: advancing ERNA-101 into a first-in-human clinical study in platinum-resistant ovarian cancer (PROC).

Importantly, the decision to prioritize ERNA-101 does not reflect a change in Ernexa’s conviction in ERNA-201 or its underlying biology. Rather, following the positive ERNA-201 proof-of-concept results, the Company believes it has reached an appropriate point to preserve the program while directing near-term resources toward achieving clinical validation of its platform in oncology.

“We believe the ERNA-201 results are an important validation of both the program and the broader potential of our synthetic iMSC platform,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “ERNA-201 did what we wanted to see at this stage: it generated an encouraging proof-of-concept signal in an established inflammatory disease model and demonstrated the potential to engineer our iMSCs for therapeutic activity beyond cancer. That success gives us the confidence to preserve the significant future opportunity represented by ERNA-201 while concentrating our resources on the milestone directly ahead of us, bringing ERNA-101 into the clinic.”

Mr. Luther continued, “Our objective is bigger than advancing a single candidate. We are building a differentiated oncology company around a scalable, off-the-shelf cell therapy platform. With ERNA-101 on track for FDA IND submission before year end, we believe Ernexa is approaching a potentially defining inflection point. We intend to execute against that milestone with urgency while broadening our oncology pipeline and identifying additional cancers where our platform could make a meaningful difference.”

ERNA-201: Positive Data Strengthen Validation of Ernexa’s iMSC Platform

ERNA-201 is engineered to express anti-inflammatory factors designed to target inflammation and treat autoimmune disease. In completed preliminary studies, ERNA-201 was evaluated in the CIA model, which is widely used to assess potential therapies for rheumatoid arthritis and other inflammatory joint diseases.

Mice treated with several ERNA-201 lead candidates demonstrated reductions in disease severity relative to untreated controls, including improvements in clinical arthritis scores. Ernexa believes the findings are consistent with the candidate’s intended anti-inflammatory mechanism and provide meaningful proof-of-concept support for the use of synthetic, cytokine-engineered iMSCs in inflammatory and autoimmune disease.

“Seeing disease-modifying activity from ERNA-201 in the collagen-induced arthritis model is an encouraging scientific result,” said Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics. “These findings support the underlying thesis that engineered iMSCs can serve as a versatile therapeutic delivery platform. We designed ERNA-201 to deliver anti-inflammatory factors in disease, and the preliminary activity we observed is consistent with that objective. From a scientific perspective, these data increase our confidence in the program and provide another important validation point for the broader platform.”

The ERNA-201 results are particularly important to Ernexa because the program employs the same fundamental synthetic iMSC platform architecture that underpins the Company’s broader pipeline. While ERNA-201 is engineered for anti-inflammatory activity and ERNA-101 is engineered to stimulate an immune response against cancer, both programs demonstrate the potential versatility of an allogeneic, scalable cell platform that can be engineered for distinct therapeutic purposes.

Building Momentum Toward the Clinic: ERNA-101 Advancing Toward Planned IND Submission in Q4 2026

With ERNA-201 generating positive preliminary proof-of-concept data, Ernexa is prioritizing the next major milestone in the Company’s evolution: advancing ERNA-101 toward a planned IND submission for a first-in-human clinical study in platinum-resistant ovarian cancer.

ERNA-101 is Ernexa’s lead oncology cell therapy candidate, engineered to express an IL-7/IL-15 fusion cytokine designed to activate and regulate the immune system’s response to recognize and attack cancer cells.

The Company is focused on advancing ERNA-101 toward a planned IND submission in the fourth quarter of 2026. Ernexa believes achieving this milestone would represent an important step toward the Company’s transition from a preclinical development company to a clinical-stage oncology company and the generation of human clinical evidence necessary to evaluate the therapeutic potential of its platform.

Clinical data from the ERNA-101 PROC study are expected in Q4 2027, providing the Company with a series of potential clinical and operational milestones over the coming 12–18 months.

A Focused Oncology Strategy Built Around One Scalable Platform

Ernexa’s strategy extends beyond a single indication or product candidate. The Company’s proprietary platform begins with induced pluripotent stem cells (iPSCs), which are engineered and transformed into synthetic induced mesenchymal stem cells. The resulting allogeneic iMSCs are designed to provide a scalable, off-the-shelf therapeutic approach without the need for patient-specific cell harvesting.

Management believes this architecture creates the potential to engineer iMSCs with different therapeutic factors and apply the platform across multiple diseases. The positive preliminary ERNA-201 findings provide additional support for that platform thesis, while ERNA-101 now represents the Company’s most advanced opportunity to demonstrate its potential in patients.

As Ernexa moves toward the clinic, the Company intends to broaden the scope of its oncology program by evaluating additional high-need cancer indications and advancing next-generation iMSC candidates designed to build on the Company’s existing scientific and manufacturing capabilities.

The Company will prioritize opportunities based on scientific rationale, unmet patient need, commercial potential and capital efficiency, including opportunities that may be pursued internally or through strategic collaborations.

Disciplined Capital Allocation: Advancing the Nearest Value-Creating Milestones

Following the encouraging ERNA-201 results, Ernexa has elected to pause additional preclinical development expenditures on ERNA-201 at this time and preserve the program while concentrating near-term resources on ERNA-101 and the expansion of its oncology pipeline.

The decision is a capital allocation priority rather than a scientific decision to discontinue ERNA-201. The Company believes the positive preliminary results provide a foundation from which ERNA-201 could potentially be advanced in the future as resources, strategic priorities and development opportunities warrant.

“We have achieved an important objective with ERNA-201 by generating encouraging proof-of-concept data,” Luther said. “The question for us now is not whether we believe in the program. We do. The question is where each incremental dollar and each hour of our team’s effort can have the greatest impact today. With ERNA-101 approaching the clinic, we believe concentrating resources behind first-patient dosing and expanding our oncology opportunity is the most disciplined path forward.”

“We are preserving ERNA-201’s future potential while accelerating the program that is closest to human clinical validation. We believe that the combination of scientific validation, disciplined execution and a clear path into the clinic positions Ernexa for an important next chapter.”

Multiple Potential Catalysts Ahead

Over the coming 12–18 months, Ernexa intends to:

  • Submit ERNA-101 IND in Q4 2026 for a first-in-human clinical study in platinum-resistant ovarian cancer;
  • Generate clinical data from the ERNA-101 PROC program, currently expected in Q4 2027;
  • Continue generating translational and preclinical evidence designed to strengthen validation of the synthetic iMSC platform;
  • Evaluate opportunities to expand the platform into additional high-need oncology indications;
  • Advance next-generation synthetic iMSC oncology candidates;
  • Explore strategic collaborations that could accelerate or broaden the application of Ernexa’s technology; and
  • Maintain disciplined capital allocation focused on milestones management believes can create the greatest value for patients and shareholders.

“We believe we are entering one of the most consequential periods in Ernexa’s development,” Luther concluded. “ERNA-201 has provided encouraging evidence that our engineering approach can translate into therapeutic activity in a well-established disease model. ERNA-101 is approaching the clinic. And behind it is a platform we believe can be engineered and deployed against multiple high-need cancers. Our focus now is execution, reaching the clinic, generating human data and building a broader oncology pipeline capable of creating sustainable value.”

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: the Company’s ability to advance ERNA-101 toward and submit an IND application to the FDA, including the planned submission in Q4 2026; the timing, design and outcomes of the planned first-in-human clinical study of ERNA-101 in platinum-resistant ovarian cancer, including the expected availability of clinical data in Q4 2027; the Company’s ability to transition from a preclinical-stage company to a clinical-stage company; expectations regarding the versatility and therapeutic potential of the Company’s synthetic iMSC platform, including its ability to be engineered for distinct therapeutic purposes across oncology and other disease areas; the Company’s plans to broaden its oncology pipeline by evaluating additional high-need cancer indications and advancing next-generation iMSC candidates; the Company’s ability to identify, develop and advance additional product candidates; the Company’s capital allocation strategy, including the decision to pause additional preclinical development expenditures on ERNA-201 and concentrate near-term resources on ERNA-101 and oncology pipeline expansion; the potential for ERNA-201 to be advanced in the future; the Company’s ability to enter into strategic collaborations or partnerships; the sufficiency of the Company’s capital resources to fund planned operations and achieve anticipated milestones; the Company’s ability to obtain and maintain regulatory approvals for its product candidates; the Company’s ability to attract and retain qualified personnel; the Company’s ability to protect its intellectual property and proprietary technology; competition from other companies developing therapies for the same or similar indications; and general market, political and economic conditions. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Argo completes rapid deployment of smart transit infrastructure and service across three Caledon communities in approximately three months

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Argo Corporation (TSXV: ARGH) (OTCQX: ARGHF) (“Argo” or the “Company”), a leader in next-generation public transit solutions, today announced the launch of its proprietary Smart Routing™ transit infrastructure and service in the Town of Caledon, expanding Argo’s network to a third municipality.

Caledon Mayor, Councillors and staff with Argo management

Caledon Mayor, Councillors and staff with Argo management

The service operates across Bolton, Caledon East and Mayfield West/Southfields. Riders can request trips through the Argo Transit app or by phone, travel point-to-point within and between the three service areas, and connect with GO Transit, Brampton Transit and York Region Transit. As previously announced, the agreement provides an aggregate fee to Argo of approximately $4.5 million over its initial 15-month term, excluding additional potential fare revenue retained by Argo.

Growing communities globally need more convenient access to transit, while governments are allocating significant infrastructure and operating funding to expand it. Argo’s patent-pending Smart Routing™ solution is designed to help municipalities and transit agencies turn that need and funding into operating transit infrastructure faster, while improving access and service efficiency.

  • Access: Smart Routing™ extends the reach of existing transit networks by picking riders up near their door and connecting them into fixed-route transit for longer journeys. In Brampton, the service is PRESTO-integrated and connects riders into Brampton Transit and GO Transit.
  • Economics: Smart Routing™ is designed to deliver broader, more convenient service efficiently as ridership scales. In Bradford West Gwillimbury, average daily ridership more than doubled while cost per ride declined by more than 50%.
  • Deployment: Smart Routing™ lets municipalities deploy a complete transit network quickly through one integrated smart infrastructure platform spanning vehicles, charging, technology and operations. In Caledon, service launched approximately three months after contract signing.

“We built Smart Routing™ so public transit can meet people where they are, connect riders seamlessly across local and regional networks, and be deployed in weeks and not years,” said Praveen Arichandran, Co-founder and CEO of Argo. “Caledon went from agreement signing to a fully operating electric Smart Routing™ transit network across three communities in approximately three months. We believe this is an infrastructure model that can scale to growing communities around the world.”

For additional information about the Caledon service, visit rideargo.com/caledon.

About Argo

Argo delivers the first-ever vertically and publicly integrated city transit system, designed to augment public transportation and create a network of intelligently routed vehicles that work together to serve and scale to the needs of entire cities, putting people in control of their mobility. Learn more at www.rideargo.com.

Investor Contact Media Contact
Praveen Arichandran Christina Ra
Co-founder & CEO Argo Corporation
Argo Corporation christina@rideargo.com
(800) 575-7051 (800) 575-7051


Forward-Looking Information

This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. The forward-looking information set out in this news release relates to future events or future performance and includes, without limitation, statements concerning the continued operation of the Smart Routing™ transit service in Caledon, service areas, potential term extensions, fare revenue, ridership, the anticipated benefits of Argo’s Smart Routing™ transit system, potential future expansion to other municipalities, and the Company’s business development pipeline. Such forward-looking statements are based on a number of assumptions, including: the continued successful operation of the Caledon service; maintaining the Agreement in good standing; receiving required third-party approvals, consents and integrations; operational readiness; ridership adoption levels; technology performance and reliability; and general economic conditions. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including but not limited to: operational challenges; failure to meet contractual requirements; loss of required operating authority, insurance or approvals; third-party integration delays or failures; technology failures or cybersecurity incidents; termination or non-renewal of the Agreement; regulatory changes; and general economic conditions. Additional risks and uncertainties are described in more detail in the Company’s securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and readers are cautioned against placing undue reliance thereon. The Company assumes no obligation to revise or update these forward-looking statements except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/303d0524-56d0-433f-bbe0-834d28b46c41

In addition, the Companies entered into a non-binding letter of intent that contemplates potential additional investments by Gix, which could result in Gix acquiring a majority interest in Ottonomy

TEL AVIV, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”), a dual-listed technology company, today announced that it has signed a $500,000 investment in Ottonomy, Inc. (“Ottonomy”), a U.S.-based Physical AI robotics company developing L4 autonomous robotic systems, pursuant to a simple agreement for future equity (“SAFE”).

The SAFE represents a further step in Gix’s strategy to build one intelligent management layer for robots, people, and autonomous systems. Gix’s wholly owned subsidiary, Deliverz.ai, provides the software intelligence and orchestration capabilities behind this layer, already commercially deployed in hospital logistics, while Ottonomy brings L4 autonomous navigation, purpose-built robotic platforms and experience operating autonomous systems across additional physical environments.

The SAFE represents an initial step for a contemplated broader strategic relationship between Gix and Ottonomy. On August 4, 2026, the companies entered into a non-binding letter of intent that contemplates potential additional investments by Gix, which could result in Gix first acquiring a strategic ownership interest in Ottonomy, with possible subsequent investments pursuant to which Gix could acquire a majority interest in Ottonomy. Except for the SAFE and any provisions expressly identified as binding, the contemplated subsequent transactions remain subject to due diligence, financing, the negotiation and execution of definitive agreements, required approvals and customary closing conditions.

Ottonomy has developed the Ottobot family of autonomous delivery robots for indoor and outdoor operation and has announced deployments, pilots and commercial programs across hospital and healthcare environments in multiple markets, airports, industrial and remote-site environments, and last-mile delivery. Ottonomy is also engaged in pilots and commercial programs with multinational enterprises across pharmaceuticals, aerospace, energy, and other complex industrial environments.

Ottonomy serves leading healthcare systems and enterprises including Henry Ford Health, Wellstar Health System, Hancock Health (a Mayo Clinic Care Network hospital), Sodexo, Rome Fiumicino International Airport, top-tier space technology companies, and major U.S. pharmaceutical manufacturers. Gix believes this breadth could help accelerate its strategy of extending one intelligent management layer for robots, people, and autonomous systems beyond its first proven healthcare applications.

Under the SAFE, Gix has made a $500,000 strategic investment in Ottonomy. The SAFE provides Gix with contractual rights to receive equity in Ottonomy upon certain future financing or other specified events. Upon the occurrence of certain qualifying financing events, the SAFE may convert into equity of Ottonomy in accordance with its terms. The SAFE investment is expected to close during the week of September 16, 2026, subject to the satisfaction of customary closing conditions.

“We believe our investment in Ottonomy is a natural next step for Gix,” said Amir Nardimon, Chief Executive Officer of Gix. “Our strategy is to build one intelligent management layer for robots, people, and autonomous systems. Deliverz.ai has already demonstrated this approach commercially in healthcare, while Ottonomy brings L4 autonomous robotics, advanced navigation and experience operating across a much broader range of physical environments.

“From hospitals and pharmaceutical environments to industrial sites, airports and last-mile delivery, Ottonomy’s operational footprint is highly complementary to our strategy. This strategic investment allows us to deepen our relationship as we evaluate opportunities to work together and expand our capabilities beyond our first proven healthcare applications.”

“Gix’s vision of one intelligent management layer for robots, people, and autonomous systems is closely aligned with how we see the future of Physical AI,” said Ritukar Vijay, Co-Founder and Chief Executive Officer of Ottonomy. “The next phase of autonomy will not be built around isolated robots performing isolated tasks. It will require autonomous systems, people and infrastructure to operate as part of a connected physical environment. We believe the combination of Gix and Deliverz.ai’s management-layer experience with Ottonomy’s L4 autonomy, contextual navigation and Physical AI robotics capabilities could create meaningful strategic opportunities and support the broader deployment of autonomous operations across healthcare, industrial and last-mile environments.”

About Gix Internet Ltd.

Gix Internet Ltd. is a technology company that is listed on the Nasdaq Capital Market under the symbol GIXI and on the Tel Aviv Stock Exchange under the symbol GIX. Its operating focus is Deliverz.ai, a wholly-owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the contemplated strategic relationship between Gix and Ottonomy, potential additional investments in Ottonomy, the possible acquisition of a strategic or majority ownership interest in Ottonomy, the timing and completion of the SAFE, the satisfaction of financing, approval and other closing conditions, the anticipated strategic, operational and commercial benefits of the relationship, the complementary capabilities of Gix’s, Deliverz.ai’s and Ottonomy’s technologies, the potential expansion of the Company’s technology into additional markets and operating environments, and the Company’s future growth opportunities and business strategy. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement of Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites.

Investor Relations Contact:
Michal Efraty
Investor Relations
michal@efraty.com

Court orders granted convening scheme meetings; Scheme Booklet registered with ASIC

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals exploration and mining company, today provided an update on its proposed acquisition of European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) (“European Lithium”).

Under the proposed transaction, Critical Metals Corp would acquire 100% of the issued share capital of European Lithium and all of European Lithium’s listed options by way of Court-approved schemes of arrangement under Part 5.1 of the Australian Corporations Act 2001 (Cth), comprising a scheme between European Lithium and its shareholders (the “Share Scheme”) and a scheme between European Lithium and the holders of its listed options (ASX: EUROC) (the “Option Scheme”, and together with the Share Scheme, the “Schemes”). The consideration payable under each Scheme is to be satisfied by the issue of new ordinary shares in Critical Metals Corp.

Court Orders Convening Scheme Meetings

European Lithium has announced that on September 15, 2026, the Supreme Court of Western Australia made orders under section 411(1) of the Australian Corporations Act directing European Lithium to convene meetings of its shareholders and optionholders to consider and vote on the Schemes (the “Scheme Meetings”), and approving the dispatch of the Scheme Booklet to European Lithium securityholders.

European Lithium has also convened a general meeting of its shareholders to be held immediately before the Scheme Meetings, at which shareholders will be asked to consider resolutions under Chapter 2E of the Australian Corporations Act. Implementation of each Scheme is conditional on those resolutions being approved.

Registration of the Scheme Booklet and Meeting Dates

The Scheme Booklet has been registered with the Australian Securities and Investments Commission (ASIC) and is expected to be dispatched to European Lithium securityholders on or around September 22, 2026. The Scheme Booklet contains important information regarding the Schemes, including the independent expert’s report, and will be released to the ASX and made available on European Lithium’s website.

The general meeting and the Scheme Meetings are scheduled to be held on Thursday, October 22, 2026 in West Leederville, Western Australia.

Mike Hanson, board director of Critical Metals Corp who leads the Special Committee responsible for this transaction, commented:
“The Court orders and registration of the Scheme Booklet are significant milestones and move the transaction into its final stages. We look forward to the securityholder meetings next month and to completing the combination.”

Subject to the approval of European Lithium securityholders, the approval of the Court, and the satisfaction or waiver of the remaining conditions precedent, the Schemes are expected to be implemented in November 2026. The dates referred to in this announcement are indicative only and remain subject to the Court approval process. Any changes will be announced by European Lithium on the ASX.

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next-generation technologies for Europe and its Western world partners. Its flagship Project, Tanbreez, is one of the world’s largest rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations, including with respect to the proposed acquisition of European Lithium and the anticipated timetable for and implementation of the Schemes. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: ir@criticalmetalscorp.com
Media: pr@criticalmetalscorp.com

New regional operating hub will establish local manufacturing, integration and support capabilities and a strategic base for XTEND’s growth across Mexico and the wider region

TAMPA, Fla., Sept. 15, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND), a global Physical AI and robotics company, today announced plans to establish XFAB Mexico, a new regional manufacturing, integration and support hub in Mexico, expanding the Company’s global footprint and establishing local capabilities spanning manufacturing, system integration, technical support and customer operations.

XFABs are XTEND’s regional operating hubs, designed to bring the Company’s technology, manufacturing, integration, support and operational capabilities closer to the customers and environments where its XOS-powered robotic systems are deployed. XFAB Mexico will join XTEND’s existing global network and serve as a foundation for the Company’s growth in Mexico and the wider region.

The expansion positions XTEND closer to a significant defense and security opportunity. Mexico’s 2026 federal budget allocates approximately MXN 296.8 billion (approximately US$17.5 billion)¹ across National Defense, the Navy, and Security and Citizen Protection. Mexico’s diverse operating environments create requirements across situational awareness, personnel protection, counter-UAS and critical-infrastructure security.

“Mexico represents a significant opportunity for XTEND and another important step in expanding our global operating footprint,” said Aviv Shapira, CEO and Co-Founder of XTEND. “We are building the infrastructure to scale XOS-powered robotic capabilities globally, while developing strong local capabilities in the markets that matter. Mexico’s defense and security requirements, industrial capacity and technical talent make it a natural next step for XTEND.”

XTEND intends to work with relevant Mexican institutions and industry around Mexico-specific requirements, with defense and the evolving needs of the Mexican Armed Forces expected to be an important initial focus, alongside national and public security and critical-infrastructure protection.

The operation will be led by Michaelle Fastlicht, General Manager of XTEND Mexico, with a focus on establishing XTEND’s local capabilities and relationships across Mexico’s government, defense, security, industrial and technology ecosystems.

“Mexico has the talent, industrial depth and ambition to play a meaningful role in the future of advanced robotics,” said Fastlicht. “Our goal is to build in Mexico, for Mexico—combining XTEND’s proven technology with Mexican talent and capabilities around the country’s specific requirements.”

XFAB Mexico is intended to incorporate local technical talent, suppliers, training and support as the operation grows, creating a foundation for XTEND to expand its capabilities in Mexico and the wider region.

++++++++++++++++++++++++++++

¹ Source: Mexico’s Presupuesto de Egresos de la Federación para el Ejercicio Fiscal 2026, published by the Diario Oficial de la Federación, allocates MXN 170.75 billion to National Defense, MXN 65.93 billion to the Navy, and MXN 60.11 billion to Security and Citizen Protection, for a combined approximately MXN 296.8 billion. The approximate U.S. dollar equivalent was calculated using Banco de México’s published exchange rate of MXN 16.9707 per U.S. dollar on September 14, 2026.

Mexico 2026 Federal Expenditure Budget — Diario Oficial de la Federación
Banco de México — Exchange Rate Source

++++++++++++++++++++++++++++

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding XTEND’s plans to establish XFAB Mexico, the anticipated capabilities and benefits of the new regional operating hub, XTEND’s strategy for growth in Mexico and the wider region, and the defense and security opportunity that Mexico may represent for XTEND. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including XTEND’s ability to establish and operate XFAB Mexico as planned, the timing and size of orders from government and defense customers, geopolitical and economic conditions in Mexico and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND is a leader in software systems and Physical AI, deployed in high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (XOS), XTEND’s integrated software and advanced robotic hardware solutions are designed to provide autonomy at the edge. Operating across Defense, Homeland Security, and Commercial Security missions through a platform of robots, drones, and robotic subsystems, XTEND’s open architecture platform facilitates scalability across partners and third-party applications. With over 12,500 systems deployed in over 30 countries, XTEND’s solutions have been validated in five combat zones and operationally deployed by national defense, special-mission units, and security organizations across the globe. Founded in Tel Aviv, Israel, and headquartered in Tampa, Florida, XTEND delivers NDAA-compliant solutions through a global network of regional XFAB manufacturing facilities located in the U.S., the U.K., Singapore, Israel, and Latvia.

Contacts

XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.